Pay in 4 interest-free payments of $7.38 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Go to your cart
Tirzepatide Tirzepatide is a dual GLP-1 and GIP receptor agonist designed to target multiple metabolic pathways
GLP-1Ra at doses intended for T2D management Studies have examined the risk of fracture in both obese and non-obese individuals taking GLP-1Ra at doses intended for T2D (such as liraglutide 1.2 mg daily versus 3.0 mg daily for obesity) [75,76,77]
That window is essentially closed
Many patients find shakes easier to tolerate 3-7 days after their weekly injection when nausea subsides, and spreading protein intake across multiple small servings throughout the day optimizes tolerance and muscle protein synthesis
